{"id":"W4396507005","doi":"10.1371/journal.pone.0298770","title":"Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma","year":2024,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"MSD K.K.; Gilead Sciences; EA Pharma Co., Ltd.; Eisai; AbbVie; Eisai Canada","keywords":"Medicine; Bevacizumab; Hepatocellular carcinoma; Internal medicine; Atezolizumab; Lenvatinib; Gastroenterology; Discontinuation; Oncology; Cancer; Sorafenib; Chemotherapy; Immunotherapy; Nivolumab","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006133582,0.0002042103,0.0005958044,0.0002733138,0.0001226699,0.0002771972,0.0001284464,0.0002129164,0.0003415499],"category_scores_gemma":[0.001018147,0.00005567056,0.0003126584,0.0001653334,0.0001092021,0.0002268439,0.0001307805,0.0002797193,0.00007477738],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002595415,"about_ca_system_score_gemma":0.0002678889,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002366504,"about_ca_topic_score_gemma":0.0006984699,"domain_scores_codex":[0.9997788,0.0001004057,0.000027828,0.000032515,0.00003649998,0.00002405139],"domain_scores_gemma":[0.9995746,0.0001440984,0.0001342859,0.00002274168,0.00003635563,0.00008787124],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01766255,0.0009943651,0.683144,0.0003989585,0.0006143037,0.001435689,0.0001231402,0.001200052,0.01860726,0.0001116053,0.000682439,0.2750256],"study_design_scores_gemma":[0.001987726,0.022364,0.9504803,0.0001328179,0.001049946,0.007231059,0.0001636273,0.004620349,0.006778122,0.0001274734,0.00503446,0.00003003853],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874308,0.01115983,0.0002734833,0.0001923541,0.00002903913,0.00002449242,0.00005110133,0.00001470574,0.0008242562],"genre_scores_gemma":[0.9986204,0.0008422484,0.0002061041,0.0000898666,0.00005414388,0.000008909028,0.0001015866,0.000001403583,0.00007518323],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0006133582,"threshold_uncertainty_score":0.003243804,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08509693328294583,"score_gpt":0.2436548772858682,"score_spread":0.1585579440029224,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}